Reliance Life Sciences Private Limited — Bortezomib Exporter Profile
Indian Pharmaceutical Exporter · #14 for Bortezomib · $125.3K export value · DGFT Verified
Reliance Life Sciences Private Limited is the #14 Indian exporter of Bortezomib with $125.3K in export value and 11 verified shipments. Reliance Life Sciences Private Limited holds a 0.6% market share in Bortezomib exports across 4 countries. The company exports 14 pharmaceutical products worth $42.3M across 4 therapeutic categories.
Reliance Life Sciences Private Limited — Bortezomib Export Profile: Buyers & Destinations
Where Does Reliance Life Sciences Private Limited Export Bortezomib?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $70.0K | 3 | 55.9% |
| BRAZIL | $24.2K | 2 | 19.3% |
| DOMINICAN REPULIC | $14.1K | 2 | 11.3% |
| DOMINICAN REPUBLIC | $10.1K | 3 | 8.0% |
| NICARAGUA | $6.9K | 1 | 5.5% |
Reliance Life Sciences Private Limited exports Bortezomib to 5 countries. The largest destination is UNITED STATES accounting for 55.9% of Reliance Life Sciences Private Limited's Bortezomib shipments, followed by BRAZIL (19.3%) and DOMINICAN REPULIC (11.3%). These destinations reflect Reliance Life Sciences Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Bortezomib from Reliance Life Sciences Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| RXCROSSROADS 3PL LLC | UNITED STATES | $70.0K | 3 |
| SEAN DOMINICAN SRL | DOMINICAN REPULIC | $24.2K | 5 |
| CIPLA BRAZIL | BRAZIL | $24.2K | 2 |
| GENERIC PHARMA GP S.A | NICARAGUA | $6.9K | 1 |
Reliance Life Sciences Private Limited supplies Bortezomib to 4 buyers globally. The largest buyer is RXCROSSROADS 3PL LLC (UNITED STATES), followed by SEAN DOMINICAN SRL (DOMINICAN REPULIC) and CIPLA BRAZIL (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Bortezomib Export Value and How Much Does Reliance Life Sciences Private Limited Contribute?
India exported $13.7M worth of Bortezomib through 1,383 shipments from 200 suppliers to 109 countries, serving 498 buyers globally. Reliance Life Sciences Private Limited contributes $125.3K to this total, accounting for 0.6% of India's Bortezomib exports. Reliance Life Sciences Private Limited ships Bortezomib to 5 countries through 4 buyers.
What Is the Average Shipment Value for Reliance Life Sciences Private Limited's Bortezomib Exports?
Reliance Life Sciences Private Limited's average Bortezomib shipment value is $11.4K per consignment, based on 11 shipments totaling $125.3K. The largest destination is UNITED STATES (55.9% of Reliance Life Sciences Private Limited's Bortezomib exports).
How Does Reliance Life Sciences Private Limited Compare to Other Indian Bortezomib Exporters?
Reliance Life Sciences Private Limited ranks #14 among 200 Indian Bortezomib exporters with a 0.6% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($3.6M), EUGIA PHARMA SPECIALITIES LIMITED ($3.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.9M). Reliance Life Sciences Private Limited processed 11 shipments to 4 destination countries.
What Bortezomib Formulations Does Reliance Life Sciences Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BORTEZOMIB INJECTION 3.5 MG (BORTECIP 3.5MG INJ 1X10ML) | $24.2K | 2 |
| BORTEZOMIB LYOPHILIZED INJECTION 3 5 MG BORTIREL 3 5MG BATCH NO RBIH0325A | $23.4K | 1 |
| BORTEZOMIB LYOPHILIZED INJECTION 3 5 MG BORTIREL 3 5MG BATCH NO RBIH0125A | $23.3K | 1 |
| BORTEZOMIB LYOPHILIZED INJECTION 3 5 MG BORTIREL 3 5MG BATCH NO RBIH0225A | $23.3K | 1 |
| BORTEZOMIB INJECTION 3,5MG (BORTIREL 3.5MG)VLS | $9.4K | 1 |
| BORTEZOMID 3.5 (BORTEZOMIB 3.5MG) BATCH | $6.9K | 1 |
| Bortirel 3.5mg Bortezomib 3.5mg | $5.1K | 2 |
| BORTEZOMIB INJECTION 35MGBORTIREL 3.5M | $4.9K | 1 |
| BORTEZOMIB INJECTION 3 5MG BORTIREL 3 5MG | $4.8K | 1 |
Reliance Life Sciences Private Limited exports 9 distinct Bortezomib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BORTEZOMIB INJECTION 3.5 MG (BORTECIP 3.5MG INJ 1X10ML) with 2 shipments worth $24.2K.
Regulatory Requirements: Exporting Bortezomib to Key Markets
What Reliance Life Sciences Private Limited must comply with to export Bortezomib to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Reliance Life Sciences Private Limited Compare to Nearest Bortezomib Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | UNITED BIOTECH PRIVATE LIMITED | $143.6K | 19 | 4 | $7.6K |
| 13 | MILES INTERNATIONAL | $129.4K | 28 | 3 | $4.6K |
| 14 | RELIANCE LIFE SCIENCES PRIVATE LIMITED ★ | $125.3K | 11 | 4 | $11.4K |
Reliance Life Sciences Private Limited ranks #14 among 200 Indian Bortezomib exporters. Average shipment value of $11.4K compared to the market average of $68.4K. The closest competitors by value are UNITED BIOTECH PRIVATE LIMITED and MILES INTERNATIONAL.
Which Indian Ports Ship Bortezomib Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 263 | 19.0% |
| SAHAR AIR | 229 | 16.6% |
| DELHI AIR CARGO ACC (INDEL4) | 168 | 12.1% |
| DELHI AIR | 148 | 10.7% |
| HYDERABAD ACC (INHYD4) | 82 | 5.9% |
| HYDERABAD AIR | 82 | 5.9% |
| Bombay Air | 62 | 4.5% |
| Bombay Air Cargo | 32 | 2.3% |
What Other Advanced Oncology Products Does Reliance Life Sciences Private Limited Export?
Reliance Life Sciences Private Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Reliance Life Sciences Private Limited's Bortezomib Exports
RLS's export operations are influenced by a complex geopolitical landscape. The ongoing Israel-Iran tensions have disrupted Red Sea shipping routes, leading to increased freight costs and potential delays. The Pharmaceuticals Export Promotion Council of India estimates that the domestic pharma industry could face losses between ₹2,500 crore and ₹5,000 crore due to these disruptions. (medicaldialogues.in) As a significant exporter, RLS must navigate these challenges to maintain its market share and delivery timelines.
Conversely, the U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies. With the U.S. seeking to diversify its supply chains, Indian exporters like RLS could benefit from increased demand. However, the imposition of broad tariffs by the U.S. administration, with rates reaching as high as 39%, poses a risk to Indian exporters, potentially affecting nearly 55% of the country's outbound shipments to America. (apnews.com) Additionally, the India–EFTA Trade and Economic Partnership Agreement, effective from October 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially enhancing RLS's access to European markets. (en.wikipedia.org)
Reliance Life Sciences Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for RLS's export success. The company must adhere to stringent FDA, WHO, and EU GMP guidelines to ensure product quality and safety. The evolving regulatory landscape, including the EU's falsified medicines directive, necessitates continuous investment in quality assurance and compliance mechanisms. RLS's proactive approach to regulatory compliance, evidenced by its investments in state-of-the-art manufacturing facilities, positions it favorably in the global market.
About Reliance Life Sciences Private Limited
Reliance Life Sciences Private Limited exports 14 products worth $42.3M. Beyond Bortezomib, top products include Immunoglobulin, Lenalidomide, Rituximab, Trastuzumab, Kit. View the complete Reliance Life Sciences Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Bortezomib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Bortezomib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Reliance Life Sciences Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 11 individual customs records matching Reliance Life Sciences Private Limited exporting Bortezomib, covering 9 formulations to 5 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 498+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Bortezomib Export Data from Reliance Life Sciences Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Reliance Life Sciences Private Limited's Bortezomib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Reliance Life Sciences Private Limited
Full Company Profile →
14 products · $42.3M total trade · 4 categories
Bortezomib Stats
Company Overview
Top Products by Reliance Life Sciences Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Reliance Life Sciences Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Bortezomib. For current shipment-level data, contact TransData Nexus.